1 – 15 of 15
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial
Ekholm, M. LU ; Bendahl, P. O. LU ; Fernö, M. LU ; Nordenskjöld, B. ; Stål, O. and Rydén, L. LU
(2019)
In European Journal of Cancer
110.
p.53-61
Mark
- 2012
- Enhancement of associated (HW -/+)-W-+/- production in the NMSSM
- 2011
- Light Higgs bosons in phenomenological NMSSM
- Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
- 2010
-
AIB1 is a predictive factor for tamoxifen response in premenopausal women.
Alkner, Sara LU ; Bendahl, Pär-Ola LU ; Grabau, Dorthe LU ; Lövgren, Kristina LU ; Stål, O ; Rydén, Lisa LU
and Fernö, Mårten
LU
(2010)
In Annals of Oncology
21.
p.238-244
Mark
- 2009
-
Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer
Rydén, Lisa LU
; Fernö, Mårten
LU
; Stal, O
; Linderholm, B.
; Ostman, A
and Jirström, Karin
LU
(2009)
31st Annual San Antonio Breast Cancer Symposium
In Cancer Research
69(2).
p.132-132
Mark
- Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer.
- 2008
- Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast conservation surgery with or without postoperative radiotherapy
- 2005
-
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
Jirström, Karin LU ; Rydén, Lisa LU
; Anagnostaki, L
; Nordenskjold, B
; Stal, O
; Thorstenson, S
; Chebil, G
; Jonsson, P-E
; Fernö, Mårten
LU
and Landberg, Göran
LU
(2005)
In Journal of Clinical Pathology
58(11).
p.1135-1142
Mark
- 2003
- Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines
- 2001
- Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens
- DNA and cell cycle analysis as prognostic indicators in breast tumors revisited
- 2000
- Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
- 1998
- Different calculation methods for flow cytometric S-phase fraction: prognostic implications in breast cancer? The Swedish Society of Cancer Study Group
- 1994
- Inter-institutional reproducibility of flow cytometric DNA-analysis in breast carcinomas